IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process

Points To ‘Limited Value’ Of Efficacy Data; Urges Renewed Education Efforts

 
• By Dave Wallace
  
Efficacy_Sign
Comparative efficacy clinical data is largely surplus to requirements, the IGBA says • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics